Why I think AstraZeneca should be in your 2019 share portfolio

AstraZeneca plc (LON: AZN) has multiple positive catalysts and I see a buying opportunity right now.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Amidst the broader market volatility, investors are likely to be more selective as to which stocks to add to their portfolio in 2019. If you believe in holding shares for the long term, I’d suggest that you take a closer look at AstraZeneca (LSE: AZN) shares as part of your healthcare portfolio.

Year-to-date, AZN’s share price is up about 10%, despite the market volatility. Let’s take a closer look at the fundamentals that are supporting the strong performance of the shares.

Robust earnings

The company is one of the largest, most innovative pharmaceutical companies globally. Its latest earnings release in November showed a strong balance sheet and positive outlook going into 2019. Chief executive Pascal Soriot confirmed expectations that the company is to grow both organically and possibly through acquisitions — which it can afford thanks to its cash flow. Analysts are now looking for a 10%+ earnings per share (EPS) increase in the New Year.

In addition to a robust balance sheet and growing profits, the dividend yield of 3.3% makes it a worthwhile pick for risk-averse income investors who know that they can compound their returns through reinvesting dividends.

Broad pipeline

The firm’s R&D and manufacturing focus lies in cancer (oncology), cardiovascular, gastrointestinal, infection, neuroscience, and respiratory, and inflammation segments. Lynparza, Tagrisso, and Brilinta are new drugs that analysts expect to contribute to the top line.

It has several prospective drug launches in the cancer, metabolism and respiratory areas, such as Imfinzi — prescribed against lung cancer. And it is exploring new avenues for growth too. In November it announced a partnership with the Belgian Biocartis Group — a molecular diagnostics company  for obtaining lung cancer diagnostic biomarker results. Its cancer focus has seen it selling its anaesthetics medicines, as well as its antibiotics division, to raise cash for what it sees as its core areas.

What could derail the shares?

On December 11, the UK parliament will vote on the Prime Minister’s proposed Brexit deal. If the government loses the vote, the country will face more uncertainty — and that would be likely to that negatively affect the FTSE, the pound and possibly AstraZeneca shares, in spite of its strength so far this year.

Like most large pharmaceutical companies, it also faces continuous risks from generic drugs competition, especially for its Nexium, Crestor, and Seroquel brands. That means some investors may see a P/E ratio of 25 as a bit rich. Personally, I think its pipeline is strong enough to offset any threat to the bottom line.

If the share price does suffer in 2019, I would expect to see yet another takeover bid from Pfizer. In 2014, the board rejected a £55-per-share offer made by the US company but AZN’s drive to become a leader in oncology treatments means many analysts both in the UK and the US would not be surprised to see yet another offer from its erstwhile suitor.

The bottom line on the shares

AstraZeneca is a fundamentally sound company with a good track record of R&D and commercialisation success – two factors that translate into a strong balance sheet and double-digit bottom line growth next year. With a beta of around 0.65 (meaning it is one of those stocks that are less volatile than the broader market), I think it could be a strong pick for another downleg or a possible bear market in 2019.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

tezcang has no position in any of the shares mentioned. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

British union jack flag and Parliament house at city of Westminster in the background
Investing Articles

Labour winning the general election would be positive for UK stocks, says JP Morgan

One mega-bank thinks certain UK stocks could benefit following the 4 July election. This writer considers a FTSE share that…

Read more »

Older couple walking in park
Investing Articles

No savings at 40? Here’s how I’d aim to retire comfortably with FTSE 100 stocks

It's never too late to begin investing in FTSE 100 stocks for retirement. Royston Wild reveals three steps to help…

Read more »

Young Asian man drinking coffee at home and looking at his phone
Investing Articles

Down 17%, is National Grid’s share price a FTSE 100 bargain?

National Grid's share price has taken a battering following a multi-billion-pound rights issue and dividend rebasement. Is it now too…

Read more »

Environmental technology concept
Investing Articles

Up 150% this year! Can NVIDIA stock keep on soaring?

Christopher Ruane explains why NVIDIA stock has soared over 150% already this year, where it might be going -- and…

Read more »

Investing Articles

Down 44% in a year, here’s why the Aston Martin share price could keep struggling

Not only has the Aston Martin share price collapsed in recent years, our writer sees its current business performance as…

Read more »

Investing Articles

I’m considering these 2 high-growth stocks to buy as a technology investor

Our author thinks Kainos and Softcat could be two of Britain's best tech investments. He thinks the risks in the…

Read more »

Abstract 3d arrows with rocket
Investing Articles

A once-in-a-decade opportunity to buy these FTSE 100 growth shares before they rocket?

Our writer highlights two FTSE 100 growth stocks he thinks could seriously outperform as interest rates are cut and economic…

Read more »

Portrait of elderly man wearing white denim shirt and glasses looking up with hand on chin. Thoughtful senior entrepreneur, studio shot against grey background.
Investing For Beginners

Down 14% in a month, is this the FTSE 100’s biggest bargain right now?

Jon Smith mulls over whether he should buy one of the worst-performing FTSE 100 stocks based on it being an…

Read more »